Premium
Sunitinib‐induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma
Author(s) -
Rautiola Juhana,
Donskov Frede,
Peltola Katriina,
Joensuu Heikki,
Bono Petri
Publication year - 2016
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.12940
Subject(s) - sunitinib , medicine , renal cell carcinoma , adverse effect , biomarker , multivariate analysis , gastroenterology , oncology , urology , biochemistry , chemistry
Objectives To evaluate the clinical significance of hypertension ( HTN ), neutropaenia and thrombocytopaenia as possible new biomarkers of sunitinib efficacy in non‐trial patients with metastatic renal cell carcinoma ( mRCC ). Patients and Methods In all, 181 consecutive patients with mRCC were treated with sunitinib; 39 (22%) received sunitinib 50 mg/day 4 weeks on/2 weeks off, 80 (44%) received 37.5 mg/day continuously and 62 (34%) received 25 mg/day continuously as their starting dose. Treatment‐induced adverse events ( AEs ) and their impact on outcome were analysed on multiple sunitinib doses. Results During sunitinib treatment 60 patients (33%) developed ≥grade 2 HTN , 88 (49%) ≥grade 2 neutropaenia and 135 (75%) ≥grade 1 thrombocytopaenia. These AEs were associated significantly with longer progression‐free survival ( PFS ; 15.7 vs 6.7; 14.6 vs 6.9; 10.4 vs 4.2 months, respectively; P < 0.001) and overall survival ( OS ; 37.5 vs 16.2; 33.7 vs 13.2; 22.3 vs 13.2 months, respectively, P ≤ 0.008). Although only neutropaenia was associated with a significantly improved PFS and OS in all sunitinib doses, a similar trend was also seen with HTN and thrombocytopaenia in all sunitinib doses. In multivariate analysis, HTN and neutropaenia were significantly associated with PFS and OS and thrombocytopaenia was significantly associated with PFS . In a 12‐week landmark analysis, HTN and thrombocytopaenia were significantly associated with PFS and OS . Patients who developed all three AEs (a favourable biomarker profile) had significantly better outcome than patients without these AEs (a poor biomarker profile); response rate 47% vs 4%, median PFS 27.1 vs 3.5 months and OS not reached vs 5.3 months (all P < 0.001). Conclusion HTN , neutropaenia and thrombocytopaenia were all biomarkers of sunitinib efficacy in patients with mRCC . Our results may help to individualise sunitinib dosing during therapy based on these common sunitinib‐related AEs .